Out of 353 patients in the MM-009 and MM-010 studies who received lenalidomide/dexamethasone, 45.6% were aged 65 or over.
353- st MM- 009 ja MM- 010 uuringute patsiendist, kes said raviks lenalidomiidi ja deksametasooni, olid 45, 6% 65- aastased või vanemad.